 Jennifer Kwak
Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 10 | 2023 | 115 | 1.480 |
Why?
| | Positron-Emission Tomography | 12 | 2023 | 260 | 1.480 |
Why?
| | Sentinel Lymph Node | 5 | 2019 | 37 | 1.220 |
Why?
| | Sentinel Lymph Node Biopsy | 6 | 2019 | 99 | 1.160 |
Why?
| | Melanoma | 8 | 2019 | 620 | 1.070 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 427 | 0.920 |
Why?
| | Multimodal Imaging | 6 | 2016 | 89 | 0.860 |
Why?
| | Skin Neoplasms | 6 | 2019 | 754 | 0.850 |
Why?
| | Fever of Unknown Origin | 1 | 2023 | 7 | 0.840 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 10 | 0.830 |
Why?
| | Thyroid Neoplasms | 3 | 2020 | 271 | 0.780 |
Why?
| | Radiopharmaceuticals | 10 | 2023 | 158 | 0.760 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 9 | 0.720 |
Why?
| | Graves Disease | 1 | 2020 | 34 | 0.710 |
Why?
| | Spirituality | 1 | 2020 | 69 | 0.640 |
Why?
| | Lung Neoplasms | 8 | 2023 | 2159 | 0.590 |
Why?
| | Positron Emission Tomography Computed Tomography | 5 | 2023 | 67 | 0.580 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2016 | 40 | 0.560 |
Why?
| | Iodine Radioisotopes | 4 | 2020 | 126 | 0.500 |
Why?
| | Tomography, X-Ray Computed | 7 | 2016 | 2272 | 0.500 |
Why?
| | Rectal Neoplasms | 1 | 2016 | 122 | 0.490 |
Why?
| | Hamartoma | 1 | 2015 | 20 | 0.480 |
Why?
| | Four-Dimensional Computed Tomography | 4 | 2021 | 25 | 0.430 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 278 | 0.400 |
Why?
| | Immunotherapy | 1 | 2015 | 473 | 0.370 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2020 | 850 | 0.360 |
Why?
| | Radiation Pneumonitis | 2 | 2021 | 24 | 0.350 |
Why?
| | Adenocarcinoma | 1 | 2016 | 787 | 0.340 |
Why?
| | Lung | 5 | 2023 | 3521 | 0.330 |
Why?
| | Neuroendocrine Tumors | 2 | 2022 | 85 | 0.300 |
Why?
| | Chemoradiotherapy | 2 | 2020 | 187 | 0.290 |
Why?
| | Lymph Node Excision | 2 | 2019 | 140 | 0.290 |
Why?
| | Respiratory-Gated Imaging Techniques | 2 | 2016 | 10 | 0.260 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 4 | 2023 | 75 | 0.250 |
Why?
| | Humans | 33 | 2023 | 114045 | 0.230 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 3 | 2021 | 117 | 0.230 |
Why?
| | Esophageal Neoplasms | 2 | 2018 | 270 | 0.220 |
Why?
| | Lymphatic Metastasis | 3 | 2019 | 275 | 0.220 |
Why?
| | Retrospective Studies | 10 | 2022 | 12521 | 0.210 |
Why?
| | Aged | 13 | 2022 | 18969 | 0.200 |
Why?
| | Neoplasms | 1 | 2015 | 2086 | 0.190 |
Why?
| | Radioisotopes | 2 | 2022 | 28 | 0.180 |
Why?
| | Middle Aged | 14 | 2020 | 26605 | 0.180 |
Why?
| | Methimazole | 1 | 2020 | 6 | 0.180 |
Why?
| | Antithyroid Agents | 1 | 2020 | 12 | 0.180 |
Why?
| | Aged, 80 and over | 8 | 2020 | 6306 | 0.180 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 30 | 0.170 |
Why?
| | Nuclear Medicine | 1 | 2019 | 7 | 0.170 |
Why?
| | Religion | 1 | 2020 | 64 | 0.170 |
Why?
| | Treatment Failure | 1 | 2020 | 330 | 0.170 |
Why?
| | Scalp | 1 | 2019 | 29 | 0.160 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 115 | 0.160 |
Why?
| | Male | 18 | 2020 | 55396 | 0.160 |
Why?
| | Prognosis | 5 | 2019 | 3315 | 0.160 |
Why?
| | Thyroid Gland | 1 | 2019 | 85 | 0.160 |
Why?
| | Skin Pigmentation | 1 | 2019 | 39 | 0.160 |
Why?
| | ROC Curve | 2 | 2018 | 441 | 0.150 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2018 | 18 | 0.150 |
Why?
| | Attitude | 1 | 2020 | 228 | 0.150 |
Why?
| | Radiotherapy | 1 | 2018 | 175 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 124 | 0.140 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2016 | 224 | 0.140 |
Why?
| | Neoadjuvant Therapy | 2 | 2016 | 305 | 0.140 |
Why?
| | Lymph Nodes | 1 | 2019 | 415 | 0.140 |
Why?
| | Tretinoin | 1 | 2018 | 122 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 32 | 0.140 |
Why?
| | Bone Marrow | 1 | 2018 | 243 | 0.140 |
Why?
| | Female | 17 | 2020 | 59324 | 0.140 |
Why?
| | Lung Diseases | 1 | 2023 | 690 | 0.130 |
Why?
| | Software Validation | 1 | 2016 | 7 | 0.130 |
Why?
| | Lymphoma | 1 | 2017 | 176 | 0.130 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2016 | 19 | 0.130 |
Why?
| | Pulmonary Ventilation | 3 | 2021 | 72 | 0.130 |
Why?
| | Societies, Medical | 1 | 2019 | 655 | 0.130 |
Why?
| | Dacarbazine | 1 | 2015 | 99 | 0.130 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2016 | 68 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 193 | 0.120 |
Why?
| | Area Under Curve | 1 | 2016 | 273 | 0.120 |
Why?
| | Disease-Free Survival | 4 | 2019 | 618 | 0.120 |
Why?
| | Octreotide | 1 | 2015 | 25 | 0.120 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 81 | 0.120 |
Why?
| | Adult | 9 | 2020 | 30375 | 0.120 |
Why?
| | Quinolines | 1 | 2015 | 129 | 0.120 |
Why?
| | Glycolysis | 1 | 2016 | 224 | 0.120 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2014 | 8 | 0.120 |
Why?
| | Organometallic Compounds | 1 | 2015 | 98 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 959 | 0.110 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2016 | 191 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 813 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2016 | 1356 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2016 | 9049 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2020 | 3003 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 660 | 0.100 |
Why?
| | Survival Rate | 4 | 2019 | 1638 | 0.100 |
Why?
| | Carcinoma | 1 | 2014 | 198 | 0.100 |
Why?
| | Inflammation | 1 | 2023 | 2464 | 0.100 |
Why?
| | Imaging, Three-Dimensional | 1 | 2016 | 511 | 0.100 |
Why?
| | Bone and Bones | 1 | 2015 | 277 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1381 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1690 | 0.100 |
Why?
| | Perfusion | 2 | 2023 | 147 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1257 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 577 | 0.090 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 913 | 0.080 |
Why?
| | Prospective Studies | 4 | 2023 | 6195 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2019 | 2122 | 0.080 |
Why?
| | United States | 2 | 2022 | 12137 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1875 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2014 | 966 | 0.070 |
Why?
| | Whole Body Imaging | 2 | 2018 | 19 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4392 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3039 | 0.060 |
Why?
| | Child | 1 | 2023 | 18401 | 0.060 |
Why?
| | Receptors, Somatostatin | 1 | 2022 | 24 | 0.050 |
Why?
| | Respiration | 1 | 2023 | 180 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 556 | 0.040 |
Why?
| | Pulmonary Atelectasis | 1 | 2018 | 11 | 0.040 |
Why?
| | Europe | 1 | 2019 | 332 | 0.040 |
Why?
| | Biological Transport | 1 | 2019 | 374 | 0.040 |
Why?
| | Thyroglobulin | 1 | 2018 | 17 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2018 | 243 | 0.040 |
Why?
| | Observer Variation | 1 | 2018 | 298 | 0.040 |
Why?
| | Medicare | 1 | 2022 | 661 | 0.040 |
Why?
| | Occipital Bone | 1 | 2017 | 17 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 24 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2018 | 522 | 0.030 |
Why?
| | Axilla | 1 | 2017 | 39 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1206 | 0.030 |
Why?
| | Radiology | 1 | 2018 | 137 | 0.030 |
Why?
| | Neck | 1 | 2017 | 85 | 0.030 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2016 | 14 | 0.030 |
Why?
| | Heart | 1 | 2020 | 613 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2015 | 183 | 0.030 |
Why?
| | Fluorouracil | 1 | 2016 | 152 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 258 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 911 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 925 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 262 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 873 | 0.030 |
Why?
| | Adolescent | 3 | 2018 | 17800 | 0.030 |
Why?
| | Carcinoma, Papillary | 1 | 2014 | 74 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 521 | 0.030 |
Why?
| | Preoperative Care | 1 | 2016 | 319 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1218 | 0.030 |
Why?
| | Research Design | 1 | 2018 | 919 | 0.030 |
Why?
| | Ultrasonography | 1 | 2015 | 635 | 0.030 |
Why?
| | Biopsy | 1 | 2015 | 1024 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 10444 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 1836 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 2764 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1791 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 784 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1469 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 4883 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 3338 | 0.020 |
Why?
|
|
Kwak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|